Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 58.33% is in line with its 5-year average of 60.84%, around the middle of its 5-year range (47.43%–63.31%).
1.16% below its 12-month average of 59.02%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 62.34%.
GROSS MARGIN
58.33%
GROSS MARGIN AVG TTM
59.02%
GROSS MARGIN AVG 3Y
60.60%
GROSS MARGIN AVG 5Y
60.84%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1.16%
CURRENT VS 3Y AVG
-3.74%
CURRENT VS 5Y AVG
-4.13%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+40.96%
vs the sector median at left
Market Cap
$1.46B
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
25.00%
5Y Avg
25.00%
Market Cap
$1.44B
Gross Margin
83.12%
TTM Avg
85.05%
3Y Avg
87.98%
5Y Avg
90.85%
Market Cap
$1.44B
Gross Margin
17.33%
TTM Avg
13.16%
3Y Avg
12.65%
5Y Avg
13.31%
Market Cap
$1.48B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.43B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.48B
Gross Margin
33.71%
TTM Avg
32.28%
3Y Avg
31.46%
5Y Avg
31.45%
Market Cap
$1.42B
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
75.15%
5Y Avg
50.10%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Certara, Inc. (CERT) | $1.46B | 58.33% | 59.02% | 60.60% | 60.84% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | 0.00% | 50.00% | 25.00% | 25.00% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.44B | 83.12% | 85.05% | 87.98% | 90.85% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.44B | 17.33% | 13.16% | 12.65% | 13.31% |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.48B | 0.00% | 0.00% | 0.00% | 0.00% |
| GH Research PLC (GHRS)vs › | $1.47B | 0.00% | 0.00% | 0.00% | 0.00% |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.43B | 0.00% | 0.00% | 0.00% | 0.00% |
| Phibro Animal Health Corporation (PAHC)vs › | $1.48B | 33.71% | 32.28% | 31.46% | 31.45% |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.42B | 100.00% | 100.00% | 75.15% | 50.10% |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 98.97% | 9.74% | -353.69% | -246.22% |
Gross Margin
58.3%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 62.34% |
| 2026-03-31 | 47.43% |
| 2025-12-31 | 62.21% |
| 2025-09-30 | 62.03% |
| 2025-06-30 | 61.06% |
| 2025-03-31 | 60.83% |
| 2024-12-31 | 61.87% |
| 2024-09-30 | 60.78% |
| 2024-06-30 | 57.34% |
| 2024-03-31 | 59.39% |
| 2023-12-31 | 61.29% |
| 2023-09-30 | 58.08% |
| 2023-06-30 | 59.95% |
| 2023-03-31 | 61.40% |
| 2022-12-31 | 63.31% |
| 2022-09-30 | 61.26% |
| 2022-06-30 | 57.47% |
| 2022-03-31 | 59.79% |
| 2021-12-31 | 61.13% |
| 2021-09-30 | 61.09% |
| 2021-06-30 | 60.71% |
| 2021-03-31 | 61.01% |
| 2020-12-31 | 46.00% |
| 2020-09-30 | 61.82% |
| 2020-06-30 | 66.22% |
| 2020-03-31 | 61.39% |
| 2019-12-31 | 59.24% |
| 2019-09-30 | 64.68% |
| 2019-06-30 | 61.53% |
| 2019-03-31 | 61.53% |
